Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments

Abstract

Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible.

Keywords: adverse events; hydroxychloroquine; lopinavir; pharmacodynamics; pharmacokinetics; therapeutic drug monitoring.